Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Polyphor AG
  6. Summary
    POLN   CH0106213793

POLYPHOR AG

(POLN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
11/23/2021 11/24/2021 11/25/2021 11/26/2021 11/29/2021 Date
1.62(c) 1.6(c) 1.598(c) 1.598(c) 1.598 Last
15 843 2 007 27 079 63 054 2 465 Volume
+1.25% -1.23% -0.13% 0.00% 0.00% Change
More quotes
Estimated financial data (e)
Sales 2019 0,01 M 0,01 M 0,01 M
Net income 2019 -64,7 M -69,9 M -69,9 M
Net cash position 2019 68,9 M 74,4 M 74,4 M
P/E ratio 2019 -1,35x
Yield 2019 -
Sales 2020 14,3 M 15,4 M 15,4 M
Net income 2020 -44,9 M -48,6 M -48,6 M
Net cash position 2020 25,1 M 27,1 M 27,1 M
P/E ratio 2020 -2,01x
Yield 2020 -
Capitalization 19,7 M 21,3 M 21,3 M
EV / Sales 2019 1 845x
EV / Sales 2020 4,63x
Nbr of Employees 52
Free-Float 82,3%
More Financials
Company
Polyphor AG is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast... 
Sector
Pharmaceuticals
Calendar
02/25Earnings Release
More about the company
Ratings of Polyphor AG
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about POLYPHOR AG
10/29Polyphor, EnBiotix Shareholders Green-Light Merger, Name Change
MT
10/29Polyphor AG Announces Executive Changes
CI
10/15POLYPHOR : Exempted From Public Tender Offer Obligation In Merger With EnBiotix
MT
10/14Polyphor to Seek Acquisitions
CI
09/27Polyphor AG Announces Executive Changes
CI
09/10POLYPHOR : Wraps Up Sale Of Inhaled Murepavadin To EnBiotix
MT
09/02GLOBAL MARKETS LIVE : Ford, Walmart, Apple, Volkswagen, Tesla...
09/01POLYPHOR : Signs All-Stock Merger Deal With Rare Disease Company EnBiotix
MT
09/01Polyphor AG signed a merger agreement to acquire EnBiotix, Inc.
CI
08/04POLYPHOR : Fails In Late-Stage Trial For Breast Cancer Combo Treatment
MT
08/03Polyphor Provides Final Update on the Phase III FORTRESS Study of Balixafortide in Pati..
CI
07/30POLYPHOR : To Layoff 20 Staff After Negative Results From Breast Cancer Treatment Study
MT
07/16POLYPHOR : to Halt Study of Breast Cancer Combo, Restructure by Up to 29 Positions
MT
07/16Polyphor AG Provides Update on the Future of the Fortress Study of Balixafortide and An..
CI
06/28GLOBAL MARKETS LIVE : Volkswagen, Daimler, Tesla, Burberry, UBS...
More news
News in other languages on POLYPHOR AG
11/25BOURSE ZURICH : le SMI poursuit sa progression à l'approche de la mi-journée
11/25BOURSE ZURICH : ouverture en hausse dans le sillage de mercredi
11/15AKTIEN SCHWEIZ SCHLUSS : Kaum verändert an ruhigem Handelstag
11/11BOURSE ZURICH : le SMI retrouve tout son élan à l'approche de la mi-journée
11/10AKTIEN SCHWEIZ SCHLUSS : SMI schliesst dank defensiven Schwergewichten fester
More news
Chart POLYPHOR AG
Duration : Period :
Polyphor AG Technical Analysis Chart | POLN | CH0106213793 | MarketScreener
Technical analysis trends POLYPHOR AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 1,60 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Gökhan Batur Chief Executive Officer
Hernan Levett Chief Financial Officer
Kuno Sommer Chairman
Daniel Obrecht Chief Scientific Officer
Frank T. Weber Chief Medical & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
POLYPHOR AG-80.39%21
CSL LIMITED10.18%101 196
WUXI BIOLOGICS (CAYMAN) INC.0.58%56 285
SAMSUNG BIOLOGICS CO.,LTD.5.33%48 100
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-0.80%35 680